[ Pharmaceutical Sciences Asia - ONLINE ]
E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: 10.29090/psa.2022.01.21.079Pharm Sci Asia 2022; 49(1), 5-14
 

Are immunosuppressant related to unfavorable outcomes in patients COVID-19 with autoimmune rheumatic disease?: A review of clinical evidence

Oki Nugraha Putra*, Hardiyono Hardiyono, Mia Arum Anggraini

- Department of Clinical Pharmacy, Program Study of Pharmacy, Hang Tuah University, Arief Rahman Hakim 150, Surabaya, East Java-Indonesia


The impact of immunosuppressant therapy in COVID-19 patients with autoimmune rheumatic disease remains unclear based on previous studies. Here, we reviewed the clinical evidence to evaluate COVID-19 patients with rheumatic disease outcomes, which previously used immunosuppressant therapy to control the disease. We used PubMed and Science Direct database to search literature up to April 2021 for publications with confirmed COVID-19 infection with rheumatic disease. The outcomes of this review were the infection rate of COVID-19 and the rate of hospitalization, ICU admission, and mortality. A total of 16 articles were included in this review. The overall rates of COVID-19 infection in patients with autoimmune rheumatic disease did not differ from the general population. Rheumatic disease patients who previously used hydroxychloroquine showed a similar infection risk of COVID-19 with those who did not use hydroxychloroquine. Furthermore, immunosuppressant therapies were associated with poor clinical outcomes, increase risk of hospitalization, ICU admission, and mortality, particularly in patients with comorbidities. The use of bDMARD, such as TNF-? inhibitor, showed a protective effect to reduce the risk of hospitalization and mortality. The administration of immunosuppressant therapy must be closely monitored in rheumatic disease patients due to unfavorable outcomes. More studies are urgently required to map risk factors of clinical outcomes with the specific immunosuppressant therapy and specific rheumatic disease.


Keyword:

COVID-19, Immunosuppressant, Autoimmune, Rheumatic disease, Outcomes




Download full paper (PDF File size: 1,490.27 KB.)





Vol.49
No.6
November-December 2022

See other volume

 


Vol.49
No.5
September-October 2022

See other volume

 


Vol.49
No.4
July-August 2022

See other volume

 


Vol.49
No.3
May-June 2022

See other volume

 


Vol.49
No.2
March-April 2022

See other volume

 


Vol.49
No.1
January-February 2022

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register



Pharmaceutical Sciences Asia by Faculty of Pharmacy, Mahidol University, Thailand is licensed under CC BY-NC-ND 4.0

    Copyright © 2017-2022
    Faculty of Pharmacy, Mahidol University, THAILAND
 

We use Cookies

This site uses cookies to personalise your experience and analyse site traffic. By Clicking ACCEPT or continuing to browse the site you are agreeing to our use of cookies.